Search Results - "Sandhu, S.K"

Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer by Sandhu, S.K., Omlin, A., Hylands, L., Miranda, S., Barber, L.J., Riisnaes, R., Reid, A.H., Attard, G., Chen, L., Kozarewa, I., Gevensleben, H., Campbell, J., Fenwick, K., Assiotis, I., Olmos, D., Yap, T.A., Fong, P., Tunariu, N., Koh, D., Molife, L.R., Kaye, S., Lord, C.J., Ashworth, A., de Bono, J.

Get full text

352 Final Results of the First in Man Trial of MK4827, a Poly (ADP-ribose) Polymerase (PARP) Inhibitor with Antitumor Activity in BRCA Carriers and Sporadic Cancer Patients by Sandhu, S.K, Wilding, G, Schelman, W.R, Omlin, A, Kreischer, N, Carpenter, C, Iannone, R, Kaye, S, de-Bono, J.S, Wenham, R.M

Get full text

641 Transcriptomic and bioinformatic evidence for disctict roles of p38 isoforms in cutaneous melanoma by Sandhu, S.K., Adusumilli, N., Kiss, A., Friedman, A.J., Efimova, T.

Get full text

1842TiP Phase II randomized trial of two dose levels of vobramitamab duocarmazine in participants with metastatic castration resistant prostate cancer (mCRPC; TAMARACK) by de Bono, J.S., Sandhu, S.K., Fizazi, K., Sun, J., Ward, A., Antonarakis, E.S.

Get full text

Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab by Menzies, A.M., Johnson, D.B., Ramanujam, S., Atkinson, V.G., Wong, A.N.M., Park, J.J., McQuade, J.L., Shoushtari, A.N., Tsai, K.K., Eroglu, Z., Klein, O., Hassel, J.C., Sosman, J.A., Guminski, A., Sullivan, R.J., Ribas, A., Carlino, M.S., Davies, M.A., Sandhu, S.K., Long, G.V.

“…Anti-PD-1 antibodies (anti-PD-1) have clinical activity in a number of malignancies. All clinical trials have excluded patients with significant preexisting…”
Get full text

362 First in human trial of a poly(ADP)-ribose polymerase (PARP) inhibitor MK-4827 in advanced cancer patients (p) with antitumor activity in BRCA-deficient and sporadic ovarian cancers by Wenham, R.M, Sandhu, S.K, Wilding, G, Sun, L, Toniatti, C, Stroh, M, Carpenter, C, de-Bono, J, Baird, R, Schelman, W.R

Get full text

258MO Niraparib plus abiraterone acetate plus prednisone (NIRA+AAP) as first-line treatment in patients with BRCA+ metastatic castration-resistant prostate cancer (mCRPC): Second interim analysis in the Asian subgroup of the MAGNITUDE study by Saad, M., Chi, K.N., Sandhu, S.K., Attard, G., Ye, D., Li, L., Jung, W., Pang, S-T., Francis, P.S.J., Li, S., Dibaj, S., Zhang, J., Kim, W., Lopez-Gitlitz, A., Wu, D., Singh, A., De Vries, R., Zhang, L., Lee, J.Y.

Get full text

LBA84 Enzalutamide and 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer (mCRPC): A randomised, phase II trial: ENZA-p (ANZUP 1901) by Emmett, L., Subramaniam, S., Crumbaker, M., Joshua, A.M., Weickhardt, A.J., Lee, S.T., Ng, S., Francis, R.J., Goh, J.C.H., Pattison, D.A., Tan, H., Kirkwood, I.D., Sandhu, S.K., Nguyen, A., Gedye, C., Rutherford, N., Hofman, M., Martin, A., Stockler, M.R., Davis, I.D.

Get full text

LBA85 Niraparib (NIRA) with abiraterone acetate plus prednisone (AAP) as first-line (1L) therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: Three-year update and final analysis (FA) of MAGNITUDE by Chi, K.N.N., Castro, E., Attard, G., Smith, M.R., Sandhu, S.K., Efstathiou, E., Roubaud, G., Small, E.J.J., Gomes, A.J.P.D.S., Rathkopf, D., Saad, M., Gurney, H.P., Jung, W., Mason, G.E., Dibaj, S., Wu, D., Diorio, B., Lopez-Gitlitz, A., Kim, W., Olmos, D.

Get full text

1825P Molecular features of circulating tumour cells (CTCs) associate with response to 177Lu-PSMA-617 plus pembrolizumab for metastatic castration resistant prostate cancer (mCRPC) by Goode, D., Keerthikumar, S., Gupta, S., Joshua, A.M., Emmett, L., Crumbaker, M., Singer, T., Lam, E., Fernandez, L., Jimenez, E., Zhang, D., Lin, Y., Wenstrup, R.J., PASAM, A., Hicks, R., Kong, G., Hamid, A., Sandhu, S.K.

Get full text

1792P Effects of enzalutamide on overall survival +/- early docetaxel in participants aged less than 70 yrs versus greater than or equal to 70 yrs in ENZAMET (ANZUP 1304) by Horvath, L.G., Davis, I.D., Martin, A., Zielinski, R., Thomson, A., Tan, T.H., Sandhu, S.K., Reaume, M.N., Pook, D., Parnis, F., North, S., Marx, G.M., McCaffrey, J.A., McDermott, R.S., Lawrence, N., Frydenberg, M., Chowdhury, S., Chi, K.N.N., Stockler, M.R., Sweeney, C.

Get full text

158MO Niraparib with abiraterone acetate and prednisone (NIRA+AAP) as first-line therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR+) gene alterations: Asian subgroup analysis of the MAGNITUDE study by Binti Saad, M., Chi, K.N., Jung, W., Pang, S-T., Attard, G., Sandhu, S.K., Mason, G.E., del Corral, A., Wang, G., Wu, D., Diorio, B., Lopez-Gitlitz, A., Lee, J.Y.

Get full text

804P Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: 5-year results of the EORTC 1325-MG/Keynote-054 double-blinded phase III trial by Eggermont, A.M.M., Kicinski, M., Blank, C.U., Mandala, M., Long, G.V., Atkinson, V.G., Dalle, S., Haydon, A.M., Meshcheryakov, A., Khattak, A., Carlino, M.S., Sandhu, S.K., Puig Sarda, S.S., Ascierto, P.A., Lorigan, P., Grebennik, D., Ibrahim, N., Marreaud, S.I., Suciu, S., Robert, C.

Get full text

LBA44 Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: Long-term quality of life analysis results of the EORTC 1325-MG/Keynote-054 double-blinded phase III trial by Bottomley, A., Kicinski, M., Long, G.V., Mandala, M., Atkinson, V.G., Blank, C.U., Haydon, A.M., Dalle, S., Khattak, A., Carlino, M.S., Meshcheryakov, A., Sandhu, S.K., Sarda, S.S. Puig, Coens, C., Suciu, S., Grebennik, D., Krepler, C., Lorigan, P., Robert, C., Eggermont, A.M.M.

Get full text

1835P A prospective study to determine the prevalence of DNA repair defects in patients (pts) with advanced prostate cancer (PC) by Sandhu, S.K., Gotto, G., Vera-Badillo, F.E., Byun, S-S., Cutuli, H.J., Gomes, A.J.P.D.S., Helissey, C., Karsh, L.I., Peer, A., Preto, D.D., Pu, Y-S., Ravilla, R., Roubaud, G., Skoneczna, I.A., Kim, W., Espina, B., Withelder, M., Urtishak, K., Francis, P.S.J., Saad, F.

Get full text

1806P Efficacy of niraparib and abiraterone acetate plus prednisone (NIRA+AAP) in homologous recombination repair gene-altered (HRR+) metastatic castration-resistant prostate cancer (mCRPC) by tissue and/or plasma assays in the MAGNITUDE trial by Attard, G., Sandhu, S.K., Rathkopf, D., Castro, E., Saad, M., Smith, M.R., Small, E.J.J., Olmos, D., Gomes, A.J.P.D.S., Roubaud, G., Zurawski, B., Efstathiou, E., Wu, D., Diorio, B., Urtishak, K., Singh, U., Xu, Y., Lopez-Gitlitz, A., del Corral, A., Chi, K.N.N.

Get full text

577O PRINCE: Interim analysis of the phase Ib study of 177Lu-PSMA-617 in combination with pembrolizumab for metastatic castration resistant prostate cancer (mCRPC) by Sandhu, S.K., Joshua, A.M., Emmett, L., Spain, L., Horvath, L.G., Crumbaker, M., Anton, A., Wallace, R., Pasam, A., Bressel, M., Cassidy, E., Banks, P., Kumar, A.R., Alipour, R., Akhurst, T., Kong, G., Davis, I.D., Williams, S., Hicks, R., Hofman, M.

Get full text

585P Safety analysis of the phase III IPATential150 trial of ipatasertib (ipat) plus abiraterone (abi) in patients with metastatic castration-resistant prostate cancer (mCRPC) by Sternberg, C.N., Bracarda, S., de Bono, J.S., Sweeney, C., Chi, K.N., Olmos, D., Sandhu, S.K., Massard, C., Garcia, J., Schenkel, F., Chen, G., Harris, A., Hinton, H., Matsubara, N.

Get full text

Energy and carbon budgeting of traditional land use change with groundnut based cropping system for environmental quality, resilient soil health and farmers income in eastern Indian Himalayas by Ansari, M.A., Saha, Saurav, Das, Anup, Lal, R., Das, Bappa, Choudhury, B.U., Roy, S.S., Sharma, S.K., Singh, I.M., Meitei, Ch Bungbungcha, Changloi, Kl Levish, Singh, L. Somendro, Singh, N. Ajitkumar, Saraswat, P.K., Ramakrishna, Y., Singh, Deepak, Hazarika, S., Punitha, P., Sandhu, S.K., Prakash, N.

“…Energy intensive traditional cereals based monoculture often lead to high greenhouse gas emissions and degradation of land and environmental quality. Present…”
Get full text

785O PIVOT IO 001: First disclosure of efficacy and safety of bempegaldesleukin (BEMPEG) plus nivolumab (NIVO) vs NIVO monotherapy in advanced melanoma (MEL) by Diab, A., Gogas, H.J., Sandhu, S.K., Long, G.V., Ascierto, P.A., Larkin, J., Sznol, M., Franke, F.A., Ciuleanu, T-E., Muñoz Couselo, E., Perfetti, A., Lebbe, C., Meier, F., Curti, B., Rojas, C., Yang, H., Zhou, M., Ravimohan, S., Tagliaferri, M.A., Khushanlani, N.

Get full text